Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

Scandinavian Real Heart AB changes date for Extraordinary General Meeting

Scandinavian Real Heart
Download udgivelse

On October 24, 2025, the Board of Directors of Scandinavian Real Heart AB (publ) convened an Extraordinary General Meeting scheduled to be held on November 24, 2025. However, the notice has not been published in the Swedish Official Gazette, which is a statutory requirement under the Swedish Companies Act.

Due to this, the Board of Directors has decided to change the date of the Extraordinary General Meeting. A new notice has been sent out on 13 November 2025 in accordance with current regulations. The new date for the Extraordinary General Meeting is 16 December 2025 at 5:30 p.m. at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås, Sweden. Registration for the meeting will commence at 5:00 p.m.

We apologize for the inconvenience and are working to ensure that the process complies with all legal requirements.

The complete notice including appendices is available on our website:
https://www.realheart.se

Matters to be dealt with at the Annual General Meeting remain unchanged.

For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21 
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se

This information is information that Scandinavian Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-13 08:30 CET.

Attachments
Scandinavian Real Heart AB changes date for Extraordinary General Meeting

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.